Gustavo Viani Arruda

Estudo das latências das ondas dos potenciais auditivos de tronco encefálico em indivíduos normo-ouvintes

Brainstem Evoked Response Audiometry (BERA) is an objective and non-invasive method of hearing assessment which detects electrical activity from the inner ea...

Brainstem evoked response audiometry in normal hearing subjects

UNLABELLED Brainstem Evoked Response Audiometry (BERA) is an objective and non-invasive method of hearing assessment which detects electrical activity from the inner ear to the inferior colliculus. AIM To assess the hearing pathway in normal hearing individuals and compare differences associated with gender, age and ear side (left and right). STUDY DESIGN A retrospective study. MATERIALS AND METHODS Sixty normal hearing individuals, aged between 09 and 66 years old, were subjected to clinical ENT examination and audiologic tests. RESULTS Wave latencies differed significantly between males and females, although there were no differences regarding right or left ear sides. Comparing latency averages regarding age and gender we noticed important differences. By the same token, significant differences were also seen comparing this study with the information present in the handbook of the BERA device used and results published by Fukuda, in another study. CONCLUSION Knowing the great importance of BERA, it is crucial that each service develops its own standards in order to enhance the accuracy of the electrophysiological diagnosis of the hearing pathway.

Achados audiológicos em pacientes tratados com radioterapia para tumores de cabeça e pescoço

Radiotherapy has been widely used given its increase in the successful outcomes and cure of some cancers. AIM: To evaluate the functionality of the auditory system in patients who underwent radiotherapy treatment for head and neck tumors. MATERIALS AND METHODS: From May 2007 to May 2008, otorhinolaryngological and audiological evaluation (Pure Tone Audiometry (air and bone conduction), Speech Audiometry, Tympanometry, Acoustic Reflex testing and Distortion Product Otoacoustic Emissions) were performed in 19 patients diagnosed with head and neck neoplasia and treated with radiotherapy. Prospective case series study. RESULTS: 10.5% left ears and 26.3% right ears had bilateral hearing loss soon after radiotherapy according to ASHA criteria. CONCLUSIONS: Radiotherapy treatment for head and neck cancer has ototoxic effects. Early programs of auditory rehabilitation should be offered to these patients.

Audiological findings in patients treated with radio- and concomitant chemotherapy for head and neck tumors

ObjectiveTo evaluate the functionality of the auditory system in patients who underwent radiotherapy and chemotherapy treatment with cisplatin to treat head and neck tumors.Study DesignCase series with planned data collection.SettingFrom May 2007 to May 2008 by the Department of Otorhinolaryngology and the Department of Oncology/Radiotherapy at Faculdade de Medicina de Marília.Subjects and MethodsAudiological evaluation (Pure Tone Audiometry (air and bone conduction), Speech Audiometry, Tympanometry, Acoustic Reflex testing and Distortion Product Otoacoustic Emissions) was performed in 17 patients diagnosed with head and neck neoplasia and treated with chemotherapy, using cisplatin, and radiotherapy.Results12 left ears (70.5%) and 11 right ears (64.7%) presented bilateral decreased hearing soon after the treatment for the frequency 1 kHz (mild auditory damage) and for the frequency 8 kHz (more significant auditory damage).ConclusionPatients with head and neck cancer submitted to the conventional radiotherapy treatment, combined with the chemotherapy with cisplatin, presented a high incidence of decreased hearing by the end of treatment. Strong evidence was observed linking auditory alteration to the amount of radiotherapy treatment.

Radioterapia no tratamento da doença de Castleman localizada

lymphocytes. There was concentric proliferation of endothelial cells in the central portion of the lesion, and the vascular lumen contained erythrocytes. These findings confirmed the diagnosis of CD. Because CD is a lymphoproliferative disease of indeterminate behavior, a decision was made to treat the patient as an outpatient, follow-up evaluations being performed every 6 months at our thoracic surgery, oncology, and hematology outpatient clinic and chest CT scans being taken during the follow-up period. A CT scan of the chest showed a slight increase in lesion size (72 × 55 mm), the lesion having no clear cleavage plane with the left descending pulmonary artery and being therefore deemed unresectable. Therefore, in August of 2009, the patient was referred to the radiation therapy department for evaluation. Between October 5, 2009 and November 16, 2009, the patient underwent three-dimensional radiation therapy at a total dose of 40 Gy, delivered in 20 fractions by a 6-MV linear accelerator. In addition to the tumor mass, the affected pulmonary hilar, subcarinal, and paratracheal lymph nodes were included in the radiation therapy fields. After the radiation therapy, the patient reported for follow-up evaluation every 3-4 months, a chest To the Editor:

Ototoxicity After Oncologic Treatment to Head and Neck Tumors

Profa. Dra. Myriam L. Isaac Faculdade de Medicina de Ribeirão Preto Universidade de São Paulo Brasil Email: mylis@fmrp.usp.br Objective: To evaluate the functionality of the auditory system in patients who underwent exclusive radiotherapy and chemoradiotherapy treatment with cisplatin to treat head and neck tumors. Study Design Case series with planned data collection. Setting: From May 2007 to May 2008 by the Department of Otorhinolaryngology and the Department of Oncology/Radiotherapy at Faculdade de Medicina de Marília. Subjects and Methods: Audiological evaluation (Pure Tone Audiometry (air and bone conduction), Speech Audiometry, Tympanometry, Acoustic Reflex testing and Distortion Product Otoacoustic Emissions) was performed in 49 patients diagnosed with head and neck neoplasia and treated with exclusive radiotherapy (19 patients) or chemoradiotherapy (30 patients). We considered as reduction of the auditory acuity, the decrease of 20 dB in an isolated frequency or of 10 dB in two or more successive frequencies, according to the American Speech-Language-Hearing Association (ASHA) criteria. Results: 10,5% left ears and 26,3% right ears presented decreased hearing soon after the radiotherapy treatment. 57 % left ears and 70% right ears presented decreased hearing soon after the chemoradiotherapy treatment All frequencies from 0.25KHz to 8kHz showed significant auditory damage (p < 0,05). Conclusions: Patients with head and neck cancer submitted to the conventional radiotherapy treatment, combined with the chemotherapy with cisplatin, presented a high incidence of decreased hearing by the end of treatment. Strong evidence was observed linking auditory alteration to the amount of radiotherapy treatment.. OTOTOXICITY AFTER ONCOLOGIC TREATMENT TO HEAD AND NECK TUMOR Myriam L. Isaac, PhD1; Ana Helena B. Dell ́Aringa, MD2; Gustavo V. Arruda, MD2; Alfredo R. Dell ́Aringa, PhD2 Departament of Otorhinolaryngology of FMUSPRP1 / Departament of Otorhinolaryngology of FAMEMA ́s General Hospital2